

Application No. 09/720,278  
Response to Office Action dated December 14, 2006  
Paper dated May 24, 2007  
Attorney Docket No. 0702-002214

**Response Under 37 CFR 1.116**  
**Expedited Procedure**  
**Examining Group 1600**

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims**

1. (Currently Amended) Medicament for treatment and/or prevention of infections and/or inflammation caused by *Candida* species, said medicament comprising a polycationic peptide or protein in an effective amount to treat said infections and/or inflammation, and a buffer in an amount of between about 0.5-100 meq H<sup>+</sup> for maintaining the pH of treatable tissue within a pre-selected range of about 5 to 8.5, wherein the polycationic peptide or protein is selected from the group consisting essentially of:

~~human lactoferrin, bovine lactoferrin, lactoferricin, conalbumin (ovotransferrin), and hydrolysates of lactoferrin.~~

2-3. (Cancelled)

4. (Cancelled)

5. (Previously Presented) Medicament according to claim 1, wherein the buffer is selected from the group consisting essentially of carbonate, phosphate, tromethamine, and tetrahydroxypropyl ethylenediamine buffers, and/or suitable salts thereof.

6. (Previously Presented) Medicament according to claim 1, comprising at least 0.5 μmol, and wherein the buffer is present in at least 1 μmol.

7. (Previously Presented) Medicament according to claim 1, wherein the buffer is present in the range of 0.8-20 meq H<sup>+</sup> per unit dose medicament.

8. (Previously Presented) Medicament according to claim 1, further comprising one or more of the following, standard excipients, diluents and carriers.

9. (Previously Presented) Medicament according to claim 1, further comprising a standard anti-fungal, anti-bacterial, and/or antiviral agent selected from the group consisting essentially of azole compounds, 5-fluorocytosine, and polyenes.

Application No. 09/720,278  
Response to Office Action dated December 14, 2006  
Paper dated May 24, 2007  
Attorney Docket No. 0702-002214

**Response Under 37 CFR 1.116**  
**Expedited Procedure**  
**Examining Group 1600**

10. (Currently Amended) Medicament according to claim 9, wherein the antifungal agent is fluconazole which is present in the medicament in the range of 0.025 mg-50 mg.

11. (Currently Amended) Medicament for the treatment and/or prevention of infections and/or inflammation caused by Candida species, said medicament comprising bovine lactoferrin a polyeationic peptide or protein being present in the medicament at a predetermined level and a buffer in an amount of between about 0.5-100 meq H<sup>+</sup> for maintained the pH of treatable tissue within a pre-selected range of about 5 to 8.5 in order to yield a synergistic pharmaceutical effect in combination with separately administerable bacterial, fungal and viral medicaments.

12. (Currently Amended) Medicament of claim 11 wherein the polyeationic peptide or protein is selected from the group as defined in claim 1, and bovine lactoferrin is present in the medicament in an amount of at least 10 mg/ml.

13. (Currently Amended) Medicament according to claim 12, further comprising one or more antifungal agents as defined in claim 9 and/or one or more excipients, diluents or carriers as defined in claim 8.

14. (Previously Presented) Medicament according to claim 13, wherein the anti-fungal agents are present in an amount of at least 0.1 mg/ml.

15. (Currently Amended) Medicament according to claim 1 and/or pharmaceutically acceptable salts thereof having one or more of the following forms: tablet, spray, salve, gel, liquid.

16-21. (Canceled)

22. (Previously Presented) A method for the treatment and/or prevention of infections caused by bacteria, fungi, virus and the like, inflammations and/or tumors whereby an effective amount of a composition according to claim 1 is administered to a patient.

23. (Withdrawn) Medicament according to claim 1, wherein the buffer maintains the pH of treatable tissue in the range of between about 7-8.

Application No. 09/720,278  
Response to Office Action dated December 14, 2006  
Paper dated May 24, 2007  
Attorney Docket No. 0702-002214

**Response Under 37 CFR 1.116  
Expedited Procedure  
Examining Group 1600**

24. (Withdrawn) Medicament according to claim 1, wherein the buffer is citrate salts.

25. (Withdrawn) Medicament according to claim 1, comprising at least 5 or more  $\mu$ mol polycationic peptide or protein, and wherein the buffer is present in at least 2 or more  $\mu$ mos.

26. (Withdrawn) Medicament according to claim 1, further comprising a standard antifungal, anti-bacterial, and/or antiviral agent selected from the group consisting essentially of pimaricine, fungicide, and amphotericin B.

27. (Withdrawn) Medicament according to claim 1, further comprising a standard antifungal, anti-bacterial, and/or antiviral agent selected from the group consisting essentially of fluconazol, amphotericin B and 5-fluorocytosine.

28. (Withdrawn) Medicament according to claim 1, wherein the antifungal agent is present in the medicament in the range of between about 0.5-5 mg.

29. (Withdrawn) Medicament of claim 11, wherein the polycationic peptide or protein is selected from the group as defined in claim 1, and is present in the medicament in an amount of at least 20 mg/ml bodily fluid.

30. (Withdrawn) Medicament of claim 11, wherein the polycationic peptide or protein is selected from the group as defined in claim 1, and is present in the medicament in an amount of at least 60 mg/ml bodily fluid.

31. (Withdrawn) Medicament of claim 11, wherein the polycationic peptide or protein is selected from the group as defined in claim 1, and is present in the medicament in an amount of at least 100 mg/ml bodily fluid.

32. (Withdrawn) Medicament according to claim 13, wherein the antifungal agents are present in an amount of at least 0.2 mg/ml.

33. (Withdrawn) In a medicament comprised of a polycationic peptide or a protein for treatment and/or prevention of infections caused by bacteria, fungi, virus and the

Application No. 09/720,278  
Response to Office Action dated December 14, 2006  
Paper dated May 24, 2007  
Attorney Docket No. 0702-002214

**Response Under 37 CFR 1.116  
Expedited Procedure  
Examining Group 1600**

like, inflammations and/or tumors, the step comprising adding a buffer in an amount of between about 0.5 to 100 meq H<sup>+</sup> per unit dose medicament to the medicament to maintain the pH of a treatable tissue within a pre-selected range.

34. (Withdrawn) The medicament according to claim 33, wherein the buffer maintains the pH of treatable tissue in the range of between about 5 to 8.5.

35. (Withdrawn) The medicament according to claim 33, wherein the buffer maintains the pH of treatable tissue in the range of between about 7-8.

36. (Withdrawn) The medicament according to claim 33, wherein the buffer is selected from the group consisting essentially of carbonate, phosphate, tromethamine, and tetrahydroxypropyl ethylenediamine buffers, and/or suitable salts thereof.

37. (Withdrawn) The medicament according to claim 33, wherein the buffer is citrate salts.

38. (Withdrawn) The medicament according to claim 33, comprising at least 0.5 μmol, and wherein the buffer is present in at least 1 μmol.

39. (Withdrawn) The medicament according to claim 33, comprising at least 5 or more μmol polycationic peptide or protein, and wherein the buffer is present in at least 2 or more μmols.

40. (Canceled)